EUVIMEDEUVIMED entdecken
Open Access

PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells

Yinghua Geng, Lili Zhou, Yan Lou, Jiaqi Chen, Qi Liu, Ji Shen, Yanli Yang, Wenjuan Wu

Oncology Reports · 17.06.2026 · 56 (2) · 1-11

DOI: 10.3892/or.2026.9153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reports, online erschienen am 17.06.2026. Verfasst von Yinghua Geng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233000, P.R. China. Hauptthemen laut MEDLINE: Sulfonamides, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2Antineoplastic Combined Chemotherapy ProtocolsClass I Phosphatidylinositol 3-KinasesPyridinesHumansApoptosisDrug SynergismCell ProliferationU937 CellsCell Line, TumorCell Survival

Stichwörter der Autor:innen

FMS‑like tyrosine kinase 3‑internal tandem duplicationsacute myeloid leukemiacombination therapylinperlisibvenetoclax

Substanzen

SulfonamidesBridged Bicyclo Compounds, HeterocyclicvenetoclaxProto-Oncogene Proteins c-bcl-2Class I Phosphatidylinositol 3-KinasesPIK3CD protein, humanPyridinesBCL2 protein, human

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233000, P.R. China.
  • Department of Biochemistry and Molecular Biology, Bengbu Medical University, Bengbu, Anhui 233030, P.R. China.

Zitieren

APA

Geng, Y., Zhou, L., Lou, Y., Chen, J., Liu, Q., Shen, J., Yang, Y., & Wu, W. (2026). PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells. Oncology Reports, 56(2), 1-11. https://doi.org/10.3892/or.2026.9153

Vancouver

Geng Y, Zhou L, Lou Y, Chen J, Liu Q, Shen J, et al. PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells. Oncology Reports. 2026;56(2):1-11. doi:10.3892/or.2026.9153

BibTeX
@article{Geng2026,
  author = {Geng, Yinghua and Zhou, Lili and Lou, Yan and Chen, Jiaqi and Liu, Qi and Shen, Ji and Yang, Yanli and Wu, Wenjuan},
  title = {PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells},
  journal = {Oncology Reports},
  year = {2026},
  volume = {56},
  number = {2},
  pages = {1--11},
  doi = {10.3892/or.2026.9153}
}
Kostenlos starten →